Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow SOLV
Solventum Corporation (SOLV) Net income
Solventum Corporation's net income for fiscal 2025 was $1.6B, up 224.8% from $479.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.4B. Solventum Corporation ranks 4th of 54 Medical Instruments & Supplies companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.6B | 224.84% |
| FY2024 | $479.0M | (64.41%) |
| FY2023 | $1.3B | 0.22% |
| FY2022 | $1.3B | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $92.0M | 607.69% |
| Mar 2026 | $13.0M | (79.37%) |
| Dec 2025 | $63.0M | (95.02%) |
| Sep 2025 | $1.3B | 1,306.67% |
| 11 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| SOLV Solventum Corporation | $1.4B |
| ALC Alcon compare | $643.0M |
| COO The Cooper Companies, Inc. compare | $570.3M |
| WST West Pharmaceutical Services, Inc. compare | $564.9M |
| ALGN Align Technology, Inc. compare | $413.6M |
| ATR AptarGroup, Inc. compare | $362.9M |
| RGEN Repligen Corporation compare | $41.5M |
| AVTR Avantor, Inc. compare | −$578.0M |
| BAX Baxter International Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SOLV
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement